Does Taltz Effectively Treat Psoriasis?
Taltz (ixekizumab) is FDA-approved for moderate-to-severe plaque psoriasis in adults and children 6 years and older who are candidates for systemic therapy or phototherapy. It targets interleukin-17A (IL-17A), a cytokine driving psoriasis inflammation, blocking it to reduce skin plaques, scaling, and itching.[1]
Clinical trials show high efficacy. In UNCOVER-1, UNCOVER-2, and UNCOVER-3 studies, 80-90% of patients achieved PASI 75 (75% improvement in Psoriasis Area and Severity Index) by week 12, compared to 3-10% on placebo. Nearly 60% reached PASI 90 and 30-40% PASI 100 (clear or almost clear skin).[2] Long-term data from IXORA-P indicates sustained response, with 70-80% maintaining PASI 75 at 108 weeks.[3]
Real-world evidence aligns: A 2022 study of 1,200+ patients reported 75% PASI 90 at 3 months and 85% at 12 months.[4] It works faster than some IL-17 inhibitors, with visible improvement in 1-2 weeks.
How Quickly Does Taltz Start Working for Psoriasis?
Loading doses (160 mg week 0, 80 mg weeks 2, 4, 6, 8, 10, 12) yield rapid results. Itch relief often begins within days; 60-70% see 90% itch reduction by week 2. Full skin clearance takes 12-16 weeks for most.[2][5]
Taltz vs. Other Psoriasis Treatments
| Treatment | Class | PASI 90 at Week 12 | Key Difference |
|-----------|-------|---------------------|---------------|
| Taltz (ixekizumab) | IL-17A inhibitor | 60-70% | Fastest itch relief; strong for nails/scalp[2] |
| Cosentyx (secukinumab) | IL-17A inhibitor | 50-60% | Similar efficacy; Taltz edges on genitals/nails[6] |
| Tremfya (guselkumab) | IL-23 inhibitor | 70-80% | Better long-term maintenance; slower onset[7] |
| Skyrizi (risankizumab) | IL-23 inhibitor | 75% | Highest clearance rates; fewer doses/year[7] |
| Humira (adalimumab) | TNF inhibitor | 40-50% | Cheaper biosimilars; less effective head-to-head[8] |
Taltz outperforms older biologics but matches or trails newer IL-23s in clearance rates.
Common Side Effects and Risks
Upper respiratory infections (15-20%), injection-site reactions (15-20%), and fungal infections (1-3%) occur most. Serious risks include IBD flares (0.5-1%)—screen patients with history—and rare hypersensitivity. No increased TB risk vs. placebo. Long-term safety holds up to 5 years.[3][9] Pregnancy category not established; use contraception.
Who Responds Best and Who Should Avoid It?
Best for plaque psoriasis with high PASI (>10) or nail/genital involvement. 80-90% response in biologic-naive patients; 60-70% in those failed on TNFs. Avoid in active Crohn's/ulcerative colitis or hypersensitivity.[1][5] Pediatric efficacy mirrors adults (60% PASI 90 at week 12).[10]
Cost and Access for Psoriasis Patients
List price ~$6,000/month (U.S.), but copay cards reduce to $5-25/month for insured. Biosimilars not yet available. Patents expire around 2033-2034; check DrugPatentWatch.com for updates: https://www.drugpatentwatch.com/p/tradename/TALTZ.[11]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125521s052lbl.pdf
[2] Gordon et al., NEJM 2016: https://www.nejm.org/doi/full/10.1056/NEJMoa1512711
[3] Reich et al., J Am Acad Dermatol 2021: https://www.jaad.org/article/S0190-9622(20)32947-4/fulltext
[4] Menter et al., J Dermatolog Treat 2022: https://pubmed.ncbi.nlm.nih.gov/34937362/
[5] Taltz HCP Site: https://www.taltz.com/psoriasis
[6] Armstrong et al., Br J Dermatol 2020: https://academic.oup.com/bjd/article/183/6/1015/6601234
[7] Reich et al., Lancet 2017: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31778-8/fulltext
[8] Griffiths et al., Lancet 2021: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00125-3/fulltext
[9] FDA Adverse Events: https://www.fda.gov/drugs
[10] Paller et al., JAMA Dermatol 2021: https://jamanetwork.com/journals/jamadermatology/fullarticle/2782990
[11] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/TALTZ